Literature DB >> 16828003

[Hepatitis C in Spain].

Miguel Bruguera1, Xavier Forns.   

Abstract

Spain has a medium endemicity of hepatitic C infection among central Europe countries and Italy. Prevalence of anti-HCV varies among regions and it ranges from 1.6 to 2.6%, which means that there may be between 480,000 and 760,000 people infected with hepatitis C virus in Spain. The prevalence is very low in people under 20 years of age and it increases from age 30 years. Prisoners and drug addicts have the highest infectious rates, between 40 and 98%. Some populations of immigrants also have a high prevalence of HCV infection, especially people from Asia and sub-Saharan countries, whereas people from Latin America have rates lower than those in the autochtones population. Spanish people with chronic hepatitis C were mainly infected via blood transfusions, IV drug use, or during some medical and surgical hospitalization. The reduction in the use of IV drugs and the programs of needle sharing, as well as the eradication of post-transfusional hepatitis, have led to a progressive reduction in the incidence of new infections (from 6.8 per 100,000 in-habitants in 1997 to 2.3 in 2003). Preliminary data suggest that an important rate of new hepatitis C cases owe to nosocomial transmission. Transmission is almost exclusively vertical in children. In spite of a two-third reduction of incident cases of hepatitis C in Spain in last few years, it is foreseeable that the number of patients with advanced HCV liver disease attended in the health-care system will increase in forthcoming years. This is due to the fact that many, still undiagnosed patients will be likely recognized for the first time as a result of some complication of the disease. All efforts to increase the screening of hidden cases of hepatitis C in primary health-care centers, allowing a prompt treatment before an advanced stage, will have a beneficial impact both in economic and social terms.

Entities:  

Mesh:

Year:  2006        PMID: 16828003     DOI: 10.1157/13090276

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  12 in total

1.  Neurocognitive impairment is worse in HIV/HCV-coinfected individuals with liver dysfunction.

Authors:  Jyoti Barokar; Allen McCutchan; Reena Deutsch; Bin Tang; Mariana Cherner; Ajay R Bharti
Journal:  J Neurovirol       Date:  2019-07-07       Impact factor: 2.643

Review 2.  Alcoholic liver disease and hepatitis C virus infection.

Authors:  Ignacio Novo-Veleiro; Lucía Alvela-Suárez; Antonio-Javier Chamorro; Rogelio González-Sarmiento; Francisco-Javier Laso; Miguel Marcos
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

3.  Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives.

Authors:  C Badenas; J To-Figueras; J D Phillips; C A Warby; C Muñoz; C Herrero
Journal:  Clin Genet       Date:  2009-04       Impact factor: 4.438

Review 4.  Hispano-Americans in Europe: what do we know about their health status and determinants? A scoping review.

Authors:  Maria Roura; Andreu Domingo; Juan M Leyva-Moral; Robert Pool
Journal:  BMC Public Health       Date:  2015-05-07       Impact factor: 3.295

5.  How hepatitis C virus modifies the immunological profile of Sjögren syndrome: analysis of 783 patients.

Authors:  Pilar Brito-Zerón; Hoda Gheitasi; Soledad Retamozo; Albert Bové; María Londoño; Jose-Maria Sánchez-Tapias; Miguel Caballero; Belchin Kostov; Xavier Forns; Srini V Kaveri; Manuel Ramos-Casals
Journal:  Arthritis Res Ther       Date:  2015-09-10       Impact factor: 5.156

6.  Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study.

Authors:  R Boix; R Cano; P Gallego; F Vallejo; R Fernández-Cuenca; I Noguer; A Larrauri
Journal:  BMC Health Serv Res       Date:  2017-07-05       Impact factor: 2.655

7.  Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.

Authors:  César Garriga; Sandra Manzanares-Laya; Patricia García de Olalla; Pilar Gorrindo; Sabela Lens; Ricard Solà; María Martínez-Rebollar; Montserrat Laguno; Jordi Navarro; Xavier Torras; Mercè Gurguí; María-Jesús Barberá; Josep Quer; Eva Masdeu; Pere Simón; Miriam Ros; Anna de Andrés; Joan A Caylà
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

8.  Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.

Authors:  Regina Juanbeltz; Alejandra Pérez-García; Aitziber Aguinaga; Iván Martínez-Baz; Itziar Casado; Cristina Burgui; Silvia Goñi-Esarte; Jesús Repáraz; José Manuel Zozaya; Ramón San Miguel; Carmen Ezpeleta; Jesús Castilla
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

9.  Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period.

Authors:  Andrés Marco; Carlos Gallego; Joan A Caylà
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

10.  Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.

Authors:  Barbara Bertisch; Fabio Giudici; Francesco Negro; Darius Moradpour; Beat Müllhaupt; Alberto Moriggia; Janne Estill; Olivia Keiser
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.